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Joakim Andr8asson*
Abstract: The development of a fluorescent LCK inhibitor that
exhibits favourable solvatochromic properties upon binding
the kinase is described. Fluorescent properties were realised
through the inclusion of a prodan-derived fluorophore into the
pharmacophore of an ATP-competitive kinase inhibitor.
Fluorescence titration experiments demonstrate the solvato-
chromic properties of the inhibitor, in which dramatic increase
in emission intensity and hypsochromic shift in emission
maxima are clearly observed upon binding LCK. Microscopy
experiments in cellular contexts together with flow cytometry
show that the fluorescence intensity of the inhibitor correlates
with the LCK concentration. Furthermore, multiphoton mi-
croscopy experiments demonstrate both the rapid cellular
uptake of the inhibitor and that the two-photon cross section of
the inhibitor is amenable for excitation at 700 nm.
Small molecule bioactives that exhibit innate fluorescent
properties serve as highly valuable tools to probe fundamen-
tal events in healthy and diseased cells and tissue. Even more
so are those that exhibit diagnostic changes in their emissive
properties (i.e. changes in fluorescence intensity or colour) in
concert with binding to their respective biomolecular target.[1]
Such characteristics allow the researcher to distinguish
between bound and unbound molecules, gaining further
insight into subcellular localisation and the underlying
mechanisms of substrate activation or inhibition.
The prodan fluorophore (Figure 1) has been highly
utilised to probe biological systems due to its desirable
spectroscopic properties, including high fluorescence quan-
tum yield and molar absorption coefficient, pronounced
solvatochromism, good photostability as well as a large
cross section for two-photon absorption (75 GM in
EtOH).[2] To date, prodan has seen extensive use as an
environment-sensitive dye to probe the binding sites of
proteins[3] and DNA,[4] as well as the structural and dynamic
changes in cellular membrane properties.[5] Furthermore,
prodan and its analogues (Supporting Information, Figure S1)
have also demonstrated their utility as two-photon excitable
fluorophores for in-depth live-tissue imaging[6] and the
imaging of lipid membranes,[7] amyloid-b plaques,[8] and
toxic cadmium deposits in cells.[9]
The aberrant regulation of kinase enzymes is associated
with virtually all major disease areas and are therefore
regarded as important drug targets.[10] Despite the advantages
of fluorescence imaging in live cells, there are only a handful
of examples in which fluorescent kinase inhibitors have been
employed as a tool to study kinase inhibition in a cellular
Figure 1. Potential prodan-derived pyrazolopyrimidine kinase inhibi-
tors.
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setting,[11] while even fewer have been utilised for in vivo
imaging studies.[12]
In light of this, we describe herein the design, synthesis,
and photophysical as well as the biological characterisation of
small prodan-based ATP-competitive kinase inhibitors
(Figure 1). The effect of the conjugation of the linker between
the fluorescent moiety and the heterocyclic core (i.e. alkane
vs. alkyne) as well as the importance of the carbonyl group in
the prodan fluorophore was of particular interest.
The pyrazolo[3,4-d]pyrimidine heterocycle serves as an
important scaffold in a number of ATP-competitive kinase
inhibitors (Supporting Information, Figure S2).[13] We there-
fore anticipated that the introduction of the fluorescent
moiety at the 3-position of the heterocycle would readily be
accommodated in the active site, as the prodan moiety would
extend out into the hydrophobic back pocket. As the
fluorescent moiety would experience a much less polar
environment compared to aqueous solution, a fluorophore
that displays pronounced solvatochromism could therefore
report, by photonic means, that binding to the kinase has
occurred.
The prodan-derivatives were synthesised and their photo-
physical properties thoroughly evaluated (see the Supporting
Information for synthetic details). Absorption and emission
spectra of prodan and compounds 1–6 were recorded in
solvent systems of varying polarity (Table 1 and Supporting
Information, Tables S1–S2 for additional spectroscopic prop-
erties). Both prodan and 1 (Figure 1) were chosen to
represent the parent fluorophores. Prodan as well as 2 and 3
display a red-shifted absorption in aqueous solution com-
pared to aprotic solvents, while the opposite effect is observed
for 5 and 6. The absorption maximum of 4 shows very little
dependency on the solvent polarity (Table 1 and Supporting
Information, Figure S7). In comparison to prodan and the
other derivatives, the absorption maximum of 2 is signifi-
cantly red-shifted, reflecting the most extended conjugated
system (Table 1 and Supporting Information, Figure S5).
Furthermore, all compounds with an extended conjugated
system (2, 4, and 5) exhibit a higher molar absorption
coefficient compared to prodan (Table 1). As for the fluores-
cence properties, all compounds display positive solvato-
chromism (red-shifted fluorescence with increasing polarity).
It is encouraging to note that the pronounced solvatochrom-
ism is preserved also for the compounds that do not contain
the carbonyl moiety from the prodan motif (1 and 4–6 ;
Table 1 and Supporting Information, Figures S4 and S7–S9).
Compounds 2, 5, and 6 are the weakest emitters in aqueous
solution (FF< 0.01), while 3 and 4 display moderately
stronger fluorescence (FF= 0.06 and 0.03, respectively,
Table 1). However, for all derivatives in less polar organic
solvents (toluene and acetonitrile), the fluorescence quantum
yields are significantly higher, along with a pronounced blue-
shift due to the strong solvatochromism of these fluorescent
entities. In aqueous solution, it is clear that 2–6 display weaker










Prodan[e] AQ 358 18127[f ] 525 0.19 1.0
ACN 352 nd 457 0.86 3.4
Tol 350 18899 414 0.57 2.1
1 AQ[e] 314 6022[f ] 437 0.57 9.3
ACN[g] 325 nd 424 0.59 7.1
Tol[g] 325 5500 403 0.66 6.0
2[h] AQ[i] 482 20926[f ] 628 0.001 nd[j]
ACN[k] 424 nd 619 0.02 0.13
Tol[k] 422 26060 504 0.55 3.4
3 AQ 375 13832[f ] 528 0.06 0.77
ACN 360 nd 475 0.67 2.9
Tol 360 16080 432 0.74 2.0
4 AQ 350 27268[f ] 523 0.03 0.38
ACN 348 nd 456 0.71 2.4
Tol 349 29419 413 0.71 2.9
5 AQ[e] 356 29686[f ] 599 0.006 0.088
ACN[g] 367 nd 500 0.98 2.3
Tol[g] 367 26057 437 0.97 1.6
6 AQ[e] 341 3522[f ] 433 0.005 0.051
ACN[g] 360 nd 417 0.51 6.6
Tol[g] 359 3637 404 0.54 5.3
AQ=1% DMSO in 10 mm phosphate buffer (pH 7.4). ACN=acetonitrile. Tol= toluene. nd=not determined. [a] Wavelength of absorption
maximum. [b] Wavelength of emission maximum. [c] Fluorescence quantum yields were determined by taking 1,9-diphenylanthracene in cyclohexane
(FF=0.97) as a reference. [d] Average fluorescence lifetime. See Table S2 of the Supporting Information for complete lifetime data. An excitation
wavelength of 377 nm was used for all compounds, with the exception of compound 2, for which an excitation wavelength of 405 nm was used.
[e] Excitation wavelength was 350 nm. [f ] Due to poor solubility in aqueous solution at high concentrations, the molar absorption coefficient was
determined in DMSO. [g] Excitation wavelength was 360 nm. [h] Fluorescence quantum yields were determined by taking Rhodamine 6G in EtOH
(FF=0.94) as a reference. [i] Excitation wavelength was 480 nm. [j] Lifetime was too short to be resolved in the single photon counting (SPC)
experiment. [k] Excitation wavelength was 470 nm.
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fluorescence compared to the parent fluorophores prodan
and 1. Although no redox-data are available, a very likely
explanation is photoinduced electron transfer quenching,
known to be accelerated in polar media.[14]
The significant decrease in fluorescence quantum yields in
aqueous solution is also reflected in the fluorescence life-
times. With the exception of 1, all derivatives display shorter
lifetimes in aqueous solution compared to toluene and
acetonitrile (Table 1 and Supporting Information, Table S2).
These results support the notion that the internal charge
transfer state of prodan and 2–6 undergo a rapid non-
radiative decay in aqueous solution.
Due to their favourable fluorescent properties in aqueous
solution, 3 and 4 were evaluated for their ability to inhibit
protein kinases. In efforts to gauge both the efficacy and
selectivity of compounds 3 and 4, initial testing consisted of
a kinome screen against a panel of 65 kinases (at 1 mm,
Supporting Information, Table S3). This panel was selected to
reflect that of the human kinome and included examples from
each of the major kinase subfamilies. Whilst the non-
conjugated derivative 3 exhibited little to no kinase inhibition
(> 60% remaining kinase activity was observed for all 65
kinases tested), the conjugated derivative 4 exhibited strong
inhibitory properties towards Aurora-A, Blk, and LCK (,
15% remaining kinase activity). No inhibitory activity against
52 kinases (> 76% remaining kinase activity) was observed.
Cell-free IC50 assays were then performed to further assess
the inhibitory properties of 4 against Aurora-A, Blk, and LCK
(Supporting Information, Table S4). Compound 4 was found
to exhibit moderate activity against Aurora-A and Blk with
IC50 values of 222 nm and 554 nm, respectively, while an IC50
of 124 nm was obtained for LCK. In light of these results, 4 has
emerged as an interesting molecular tool in which fluores-
cence can be employed to study LCK inhibition.
Given the strong solvatochromic properties of 4 and the
hydrophobic active site of kinases, it was envisioned that
binding of the prodan-based LCK inhibitor 4may result in the
onset of intense blue-shifted emission. Fluorescence titration
experiments were undertaken to investigate this notion, in
which aliquots of a solution of 4 were added to a solution of
LCK (1 mm). Over the course of the experiment, changes in
both the emission maximum and intensity were monitored
and subsequently plotted to afford the corresponding binding
isotherm (Figure 2 and Supporting Information, Figure S11).
A dramatic increase in emission intensity as well as a blue-
shift was indeed observed upon binding LCK (at 1:1 4 :LCK,
emission intensity is 400-fold higher than for unbound 4).
After the addition of 1.0 equivalent of inhibitor, the curve
plateaued. This strongly suggests a 1:1 binding stoichiometry
to the active site. Moreover, the linear nature of the binding
isotherm below this inflection point shows that the binding is
near quantitative at all concentrations and infers that binding
is too strong to allow for the determination of the binding
constant.[15] Upon increasing the amount of inhibitor,
a second binding regime was observed (Supporting Informa-
tion, Figure S11), likely to be explained by nonspecific
binding. Displacement experiments with the non-fluorescent
ATP-competitive LCK inhibitor TC-S7003 (IC50= 7 nm)
[16]
strongly support the aforementioned notion. Upon titrating
TC-S7003 (0–2.0 equiv) to a 1:1 complex of 4 :LCK, a dramatic
decrease in emission from 4 was observed (Figure 2C),
implying that 4 binds almost exclusively to the ATP-binding
site of LCK at concentrations lower than 1 equivalent.
Fluorescence titration experiments using JAK2 (a kinase
in which 4 did not exhibit kinase activity for in the kinome
screen) in place of LCK were also performed. Upon
monitoring changes in the emission maximum and intensity,
the resulting binding isotherm shows no signs of strong
specific binding at concentrations below 1 mm (Supporting
Information, Figure S13). Furthermore, significant increases
in fluorescent intensity were not observed upon increasing
concentration of 4 (0–30 equiv).
Fluorescence microscopy was used to investigate the
properties of 4 in a cellular context. LCK-positive Jurkat cells
were incubated with 4 at concentrations of 5 nm–5mm for
15 minutes (Supporting Information, Figure S16). Strong
intracellular emission was observed at 0.5 and 5 mm, demon-
strating rapid cellular uptake (Figure 3B,C). The observed
cellular accumulation of 4 is in agreement with the reported
LCK localisation (cytosolic side of the plasma membrane,
intracellular vesicles, and the Golgi apparatus).[17] In a sepa-
rate experiment, Jurkat cells incubated with 4 at 5 mm were co-
stained with an LCK-specific antibody conjugated with
Alexa 647 (anti-LCK-AF647). Partial co-localisation was
clearly observed in intracellular vesicles, suggesting that the
observed emission intensities from 4 correlate with the
intracellular LCK concentration (Figure 3D,F).
Figure 2. A) Normalised emission spectra of 4 (blue) and 1:1 4 :LCK (red) in Tris buffer at pH 7.5. B) Changes in intensity at 442 nm upon
increasing equivalents of 4. Concentration of LCK is 1 mm. C) Changes in the emission spectrum upon the addition of TC-S7003 to 1:1 4 :LCK.
Concentration of 4 :LCK is 1 mm. Emission spectra before (black) and after the addition of 2.0 equiv (blue) of TC-S7003.
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Furthermore, LCK-negative A498 cells transfected with
a plasmid encoding wild-type untagged LCK were treated
with 4 (0.5 mm), co-stained with anti-LCK-AF647, and
analysed using microscopy (Figure 4A–C). In comparison to
the population of non-transfected cells (see Figure 4A, region
indicated by the white box), the transfected cells exhibited
a large degree of co-localisation of 4 with anti-LCK-AF647,
again supporting a high affinity of 4 for LCK.
To quantify the effect of an increased LCK concentration
on the emission intensity of 4, the LCK deficient cell line
K562 (well-suited for flow cytometry measurements) was
electroporated with the aforementioned plasmid encoding
LCK. While the efficiency of the electroporation was low
(approximately 4%), the overexpression of LCK resulted in
a significant increase (40%) in fluorescence intensity from 4
compared to the non-transfected K562 cells. The correspond-
ing increase in the fluorescence observed from anti-LCK-
AF647 (around a factor of 500) is much more pronounced
compared to 4. This is consistent with the microscopy results
in which fluorescence from unspecific binding of 4 is seen
(Figure 4B, region indicated by white box).
In efforts to demonstrate the applicability of 4 to multi-
photon fluorescence imaging, two-photon microscopy (TPM)
experiments were undertaken using the human lung cancer
cell line, HTB-177. Cells were treated with a solution of 4 at
concentrations of 0.1–10 mm for 5 minutes and images were
acquired following excitation at 700 nm. At concentrations of
0.5–10 mm strong intracellular emission was observed (Sup-
porting Information, Figure S19). These results clearly dem-
onstrate that 4 exhibits a favourable cross section for TPM
experiments.
To conclude, a small ATP-competitive LCK inhibitor
(IC50= 124 nm) with innate fluorescent properties has been
realised through the integration of a prodan-derived fluoro-
phore into the pharmacophore of the kinase inhibitor.
Fluorescence titration experiments with LCK demonstrate
a dramatic increase in emission intensity as well as a blue-shift
of the emission maximum upon binding to LCK. Further-
more, an increase in fluorescence intensity of 4 correlates with
an increase in LCK concentration, as observed in microscopy
and flow cytometry experiments, while multiphoton imaging
experiments in live cells demonstrated that compound 4
exhibits a favourable cross section for TPM experiments.
The prodan-derived LCK inhibitor could serve as a valuable
molecular tool for real-time intracellular studies of LCK
signalling, with its unique solvatochromic properties allowing
the user to distinguish between bound and unbound mole-
cules in a cellular setting.
Acknowledgements
The authors acknowledge financial support from the Euro-
pean UnionQs Horizon 2020 programme (grant no 745626);
the Swedish Research Council (grant no 2016-03601 and
2015-05268) and Olle Engkvist Byggm-stare Foundation. We
thank the Centre for Cellular Imaging at the University of
Gothenburg and the National Microscopy Infrastructure,
NMI (VR-RFI2016-00968) for providing assistance in multi-
photon microscopy. We thank Dr. Anna B-ckstrçm (KTH/
SciLifeLab, Sweden), Prof. Kjetil Task8n (University of Oslo,
Norway), Dr. Marco Maugeri, and Dr. Hadi Valadi (Univer-
sity of Gothenburg, Sweden) for providing cells. The authors
would also like to thank Dr. Quirin Hammer (Karolinska
Institutet, Sweden) for his valuable support regarding flow
cytometry and Kyra Kuhnigk (KTH, Sweden) for assistance
with some of the experiments. This work was performed in
part at the Chalmers Material Analysis Laboratory.
Figure 3. Images of Jurkat cells incubated for 15 mins with 4 at
A) 50 nm, B) 0.5 mm, and C) 5 mm. Jurkat cells co-stained with D) anti-
LCK-AF647 and E) 4 (0.5 mm), with F) showing the overlay of the two
channels. Scale bar: 25 mm.
Figure 4. Top: Images of A498 cells transfected with a plasmid encod-
ing LCK and co-stained with A) anti-LCK-AF647 and B) 4 (0.5 mm) with
C) showing the overlay of the two channels. The white box shows non-
transfected cells as indicated by the absence of anti-LCK-AF647. Scale
bar: 25 mm. Bottom: Analysis of K562 cells transfected with a plasmid
encoding LCK using flow cytometry, monitoring the fluorescence of
D) anti-LCK-AF647 from non-transfected (LCK@) and transfected
(LCK+) cells, and E) compound 4 from transfected (blue) and non-
transfected (red) cells. The orange and green peaks are the unstained
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